The Quantellect read.As of Nov 19, 2026, 9 active firms cover Immunovant Inc: 6 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $30.00 to $62.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $46.00 sits 39% above the current $33.19. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.67 next quarter toward $-2.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy667%
Neutral333%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.00
+38.6% upside
Average target across 8 active firms as of Nov 19, 2026 vs $33.19 current
Highest Target$62.00
Average Target$46.00
Lowest Target$30.00
Detailed analyst forecasts for IMVT
Showing 1–8 of 8 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 6 of 9 active firms rate IMVT a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMVT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.67
Range $-0.77 – $-0.53 · 3 analysts · -0% YoY
Next period, 3 analysts expect Immunovant Inc to earn $-0.67 a share (range $-0.77 – $-0.53), versus $-0.67 a year earlier. Full-year consensus is $-2.78, growing to $-2.75 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $34.4M next year.
Top analysts covering Immunovant Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMVT.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$62.00+86.8% to target
Overall win rate
50%
+ Follow
#2
Brian Cheng
JP Morgan · Rank #87
Buy
$50.00+50.6% to target
Overall win rate
51%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #160
Buy
$43.00+29.6% to target
Overall win rate
47%
+ Follow
#4
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$41.00+23.5% to target
Overall win rate
35%
+ Follow
#5
SS
Samantha Semenkow
Citigroup · Rank #333
Buy
$61.00+83.8% to target
Overall win rate
41%
+ Follow
IMVT stock forecast FAQ
What is IMVT's average 12-month price target?+
The 8 active firms with a live target average $46.00 for Immunovant Inc over the next 12 months, ranging from a $62.00 high to a $30.00 low, as of Nov 19, 2026.
Is IMVT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMVT?+
The Street-high target is $62.00 (Guggenheim), and the Street-low is $30.00 (Truist Securities). The average of all 8 active-firm targets is $46.00.
How many active Wall Street firms cover IMVT?+
9 active firms have a recognized rating on Immunovant Inc as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMVT?+
Among analysts who currently cover IMVT, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $62.00 target.
What is Immunovant Inc's projected EPS for next quarter?+
The consensus estimate is $-0.67 per share (range $-0.77 – $-0.53) across 3 analysts. Full-year EPS is projected at $-2.78, rising to $-2.75 the following year.
How much revenue is Immunovant Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $34.4M next year.
Have analysts been upgrading or downgrading IMVT lately?+
As of Nov 19, 2026, 6 of 9 active firms rate IMVT a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMVT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.